Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
Researchers at the University of Cincinnati are developing new imaging technologies to help accurately pinpoint deep-brain stimulation electrodes in patients with Parkinson's disease. The study aims to reduce complications and improve patient outcomes by utilizing advanced MRI sequences and diffusion tensor imaging.
A new study found that patients starting rasagiline earlier experienced less progression of Parkinson's disease symptoms and signs, including rigidity and activities of daily living. The long-term study showed a 16% less progression in the early-start group compared to those who delayed treatment for six months.
A Mayo Clinic-led international consortium discovered a genetic defect in the dynactin complex that may help explain neurodegenerative diseases like Parkinson's and amyotrophic lateral sclerosis. The mechanism implicated in Perry syndrome, a rare disorder, may also shed light on common depression and sleep disorders.
Patients with advanced Parkinson's disease who received deep brain stimulation treatment had significant improvements in movement skills and quality of life after six months. However, the treatment was also associated with a higher risk of serious adverse events, including surgical site infections and nervous system disorders.
Researchers at Emory University School of Medicine have discovered that the protein alpha-synuclein interferes with the cell's recycling of MEF2D, leading to cell death. The study suggests that targeting MEF2D could be a potential way to regulate brain cells' response to toxic stresses.
A study published in Neurology found that people with REM sleep behavior disorder have an increased risk of developing neurodegenerative diseases like dementia and Parkinson's. The five-year risk was estimated to be 18%, while the 10-year and 12-year risks were 41% and 52%, respectively.
Researchers found that CD4+ T cells play a significant role in Parkinson's disease progression. Infiltration of these immune cells in the brain contributes to neurodegeneration. Targeting the immune system might offer a new therapeutic approach.
Researchers developed a method to analyze genetic variations in HCV-infected patients, predicting their response to antiviral therapy. This approach may lead to a test that identifies targets for new antiviral drugs.
A recent study found that older antidepressants targeting both serotonin and norepinephrine are more effective in treating depression in people with Parkinson's disease. This is a significant finding, as depression affects up to 50% of individuals with the condition.
Researchers are investigating the correlation between a fading sense of smell and the onset of Parkinson's disease. The study, which draws from research demonstrating that first-degree family members have a slight increase in risk, will monitor relatives 50 years or older for early detection.
Levodopa is recommended for treating both early and advanced stages of Parkinson's disease, improving motor skills, speech, and gait. The treatment can also confirm a suspected diagnosis of Parkinson's disease, providing relief from tremors and other symptoms.
Parkin protein prompts neuronal survival by clearing damaged mitochondria. Researchers found that Parkin translocates to mitochondria upon damage, sending them to autophagosomes for degradation. This process prevents damaged mitochondria from triggering cell death.
Researchers at Southern Methodist University identified four potent chemical compounds that slow neuron degeneration, a key cause of old-age diseases like Alzheimer's and Parkinson's. The compounds, called 3-substituted indolin-2-one derivatives, are non-toxic even at high doses, offering hope for halting neurodegenerative diseases.
A recent clinical trial has shown remarkable results for patients with obsessive-compulsive disorder (OCD), with 7 out of 10 participants experiencing a substantial reduction in symptoms after deep cerebral stimulation. The treatment, which involves targeting the subthalamic nucleus in the brain, offers a promising alternative to tradi...
Researchers will investigate new ways of developing clinical trials for Alzheimer's disease and Parkinson's disease. The study aims to improve the speed, cost-effectiveness, and relevance of treatments, benefiting patients and their carers.
The Parkinson's Disease Foundation has awarded $150,000 to study the potential of individualized stem cell therapy for treating Parkinson's disease. Researchers will investigate using transformed adult skin cells to replace damaged dopamine neurons in the brains of people with Parkinson's.
A study published in Archives of Neurology found that individuals with Parkinson's disease are more likely to be vitamin D deficient compared to healthy adults and those with Alzheimer's disease. The average vitamin D concentration in the group with Parkinson's disease was lower than both groups.
A new study from Emory University School of Medicine found that 55 percent of Parkinson's disease patients had insufficient levels of vitamin D. The study also showed a higher fraction of patients with the lowest levels of vitamin D, described as deficiency, in the Parkinson's group compared to Alzheimer's and healthy groups.
The National Institute of Environmental Health Sciences is awarding three new grants to investigate the role of environmental factors in Parkinson's disease and other neurodegenerative disorders. The research will focus on identifying mechanisms that link pesticide exposure, mitochondrial damage, and altered dopamine storage to the dev...
Stuart A. Lipton will lead a center studying potential environmental causes of Parkinson's disease, examining chemical reactions that alter protein function and screening compounds to prevent disease progression. The center represents a collaborative effort between scientists at Burnham and other institutions.
A study of 402 Parkinson's disease patients found that 69.9% experienced pain, compared to 62.8% in healthy controls. Pain types included cramping and central neuropathic pain, suggesting a link between brain structures and pain processing.
Researchers used an engineered virus to deliver a glowing protein into newborn brain cells in an animal model of Parkinson's disease, revealing most cells are glial and do not form neurons. Further gene delivery experiments showed no effect on neuron formation but increased the number of oligodendrocytes supporting neurons.
Researchers have discovered unique hybrid protein complexes that form when Abeta amyloid and a-synuclein interact, altering neuronal activity. This study provides a model for developing new drugs to treat these devastating neurological diseases.
A new brain imaging study reveals that there are optimal times for multitasking, allowing individuals to be more efficient. The research found that certain brain regions show higher activity when people are performing well under multiple tasks.
Researchers at the University of Cincinnati have found that deep brain stimulation can halt the progression of dopamine-cell loss in animal models. The study suggests that stimulating neurons with electrodes boosts the amount of BDNF, a protein that promotes neuronal growth.
A team of University of Cincinnati researchers is studying the relationship between depression and Parkinson's disease to gain insight into possible treatments. In pilot models, they found that stress-induced depression exacerbates problems with movement and causes brain cells to die faster.
Researchers at the University of Pennsylvania School of Medicine have identified a baker's yeast protein, Hsp104, that can reverse protein aggregation in animal models of Parkinson's disease. This breakthrough finding holds promise for developing new treatments for the condition.
A study published in JCI Journals suggests that a yeast protein called Hsp104 may hold the key to treating Parkinson's disease. The protein was found to inhibit alpha-synuclein aggregation, which is thought to contribute to PD pathology.
Researchers found that dopamine strengthens the 'go' circuit and weakens the 'stop' circuit in the brain, leading to compulsive behavior and addictive tendencies. The study also shows how Parkinson's patients' reduced dopamine levels lead to frozen motor skills.
The Michael J. Fox Foundation has awarded $1.1 million for 15 high-risk, high-reward research projects to explore new approaches to treating Parkinson's disease using gene silencing techniques and induced pluripotent stem cell technology. The funding aims to develop transformative treatments and a cure for PD.
A team of scientists found that genes controlling heme synthesis in red blood cells also control a gene and protein causing Parkinson's disease. The study suggests that targeting the GATA-1 and GATA-2 proteins may lead to new treatments for the neurological disorder.
The Michael J. Fox Foundation has awarded $2.4 million to nine research teams to validate potential therapeutic targets for Parkinson's disease. The funding aims to accumulate evidence and reduce the risk of investment for industry, ultimately accelerating PD drug development.
Jülich scientists have discovered the mechanism behind Parkinsonian tremor and developed a new deep brain pacemaker to disrupt it. The device influences disturbed neurons in the core region of the brain, causing irregular rhythms that break down diseased modes.
The Parkinson's Disease Foundation has awarded $950,000 in seed grants to 19 researchers, including Matthew Goldberg and Sandra M. Lynch, to explore new treatments for Parkinson's disease. The funding will support the development of animal models and antibody-based therapies.
Researchers at the University of Alberta found that sprinters closest to the starter pistol had significantly lower reaction times than those farther away. The study suggests that procedures used in Olympic sprint events may give runners closer to the starter an advantage.
Researchers have found that adult stem cells from Parkinson's patients' noses can differentiate into dopamine-producing brain cells when transplanted into the brain of a rat. This breakthrough has significant implications for treating the debilitating symptoms of Parkinson's disease.
A Binghamton University researcher will receive a $1.33 million NIH grant to study the side effects of Parkinson's disease treatment, with a focus on reducing dyskinesia and suppressing abnormal motor movements. The research aims to develop new treatments that can address these issues and improve patient outcomes.
Researchers at Goethe University Frankfurt have discovered two gatekeeper proteins, Rpn13 and an ubiquitin receptor, on the proteasome. This finding has significant implications for cancer research, as it may lead to the development of targeted drugs that can block protein breakdown and prevent tumor cell proliferation.
Researchers found that activating the c-Jun gene in cultured neurons with Schwann cells promotes dedifferentiation and speeds nerve healing. The study suggests a new potential target for understanding and treating diseases like Charcot-Marie Tooth disease and Guillain-Barre syndrome.
A study of seven patients with Parkinson's disease found that re-implanting electrodes to correct placement can improve symptoms and reduce medication doses for those who had poor results after initial implantation. The procedure led to significant improvements in motor function scores and reduced levodopa medication doses.
The American Society for Neural Therapy and Repair (ASNTR) has awarded neuroscientist Paul M. Carvey for his groundbreaking research on Parkinson's Disease, while recognizing patient advocate Joan Samuelson for her tireless advocacy efforts.
A novel cell therapy using retinal pigment epithelial cells attached to gelatin bead microcarriers has shown promising results in patients with moderate to advanced Parkinson's disease. The therapy, Spheramine, has been well-tolerated and has improved symptoms such as tremor, rigidity, and balance issues for several years.
Two studies from the University at Buffalo use advanced MRI technologies to identify brain regions linked to Parkinson's disease. The research found that white matter hyperintensities are associated with lower scores on mental tests, suggesting a possible explanation for cognitive impairment in PD.
A new study by University of Minnesota researchers identifies unit burst generators in the spinal cord that control rhythmic movements such as walking. The discovery may help lead to treatments for Parkinson's disease and spinal cord injuries.
Recent research has identified seven LRRK2 gene mutations associated with Parkinson's disease, including a rare mutation that doubles the risk in ethnic Chinese. The findings suggest that genetic influences passed down through generations can significantly increase susceptibility to the disease.
Researchers found that high urate levels among recently diagnosed Parkinson's patients slowed disease progression during a two-year study period. Elevated urate levels have been linked to reduced risk of developing Parkinson's disease, and may offer new treatment strategies for the disorder.
The Michael J. Fox Foundation has awarded $5.6 million for a Phase 2 clinical trial investigating the potential of inosine to slow or stop Parkinson's disease progression. The study will determine the safety of using inosine to raise urate levels and assess optimal dosage for therapeutic effect.
A study of 804 individuals with early Parkinson's disease found that those with higher blood urate levels were less likely to progress and required dopaminergic therapy. The association suggests that urate may protect dopamine-producing neurons, potentially leading to the development of new therapies.
Scientists have identified 'mother cells' that produce dopamine-producing neurons affected by Parkinson's disease. These radial glia-like cells could be used to grow replacement neurons in the lab, potentially leading to new treatments for the disease.
A study by Medical College of Georgia found that occupational therapy using Nintendo Wii can slow disease progression, decrease medication needs, and increase function in Parkinson's patients. The therapy helps participants improve daily activities like dressing, walking, and fine motor skills.
A recent study published in Nature Medicine found that fetal cells implanted in patients with Parkinson's disease can develop Lewy body pathology, a defining characteristic of the disease. The study suggests that cell replacement strategies for Parkinson's disease may not be effective in the long-term.
A study of 42 amateur boxers found microhemorrhages in three cases, a potential precursor to Parkinson's disease and dementia. However, the differences were not statistically significant, leaving conclusive statements unclear. Further research on professional boxers is planned to assess intensive exposure to blows.
Researchers at Yale University have successfully created new neurons using uterine stem cells, which increased dopamine levels and partially corrected Parkinson's disease symptoms in mice. This breakthrough has significant implications for the development of a potential human treatment.
A family-based study found a significant association between pesticide use, particularly herbicides and insecticides, and an increased risk of developing Parkinson's disease. The research team recruited 319 patients and over 200 relatives to analyze the relationship between pesticide exposure and Parkinson's disease development.
Researchers at Memorial Sloan-Kettering Cancer Center have successfully used therapeutic cloning to treat Parkinson's disease in mice. The method involves generating customized dopamine neurons from the patient's own skin cells and transplanting them into the mouse, resulting in neurological improvement.
A genetic clue has been uncovered for Parkinson's disease, a progressive movement disorder affecting millions worldwide. GIGYF2 mutations have been found to be directly linked to the development of Parkinson's in people with a family history of the disease.
Scientists have identified genes and processes that may underlie the susceptibility to Parkinson's disease. The study found that the gene sir-2.1 has a significant effect on protein formation, which is thought to play a role in the aging process and the development of the disease.
Researchers found that impaired sense of smell can precede the development of Parkinson's disease (PD) in men by at least four years. Smell impairment was associated with an increased risk of PD, even after adjusting for other factors such as age and cognitive function.
Scripps Research will develop a compound to treat neurodegeneration in Parkinson's disease using a classical pharmaceutical approach. The goal is to bring the potential treatment to human clinical studies, aiming to have a safe and efficacious compound with sufficient preclinical safety data.
A reliable blood test for Parkinson's disease could revolutionize care and research, according to a new study. The test uses a 'metabolomic profile' to identify unique changes in dozens of small molecules in serum that are linked to the disease.